My Market Wizard

GSK plc 6-K Analysis & Summary – 2/21/2025

⚠️This is not investment advice.

⚠️ This is an experimental project and this report is for informational purposes only and should not be considered investment advice. Conduct your own thorough research and consult with a qualified financial advisor before making any investment decisions. ⚠️

GSK plc

Filing date:

02/21/2025

TLDR:

GSK plc granted deferred annual bonus plan awards to its Persons Discharging Managerial Responsibilities (PDMRs) on February 17, 2025.

ELI5:

GSK gave its top managers bonus awards in the form of company stock that they can’t access for a few years. This encourages them to focus on the long-term success of the company.

Accession #:

0001654954-25-001746

Published on

Analyst Summary

  • GSK plc granted awards to PDMRs on February 17, 2025, under the GlaxoSmithKline 2017 Deferred Annual Bonus Plan.
  • Executive Directors are required to defer 50% of bonus equivalent to the first 200% of salary into Ordinary Shares or ADS with any portion in excess of 200% being deferred in full.
  • Other members of the GSK Leadership Team are required to defer 25% of bonus equivalent to the first 170% of salary into Ordinary Shares or ADS with any portion in excess of 170% being deferred in full.
  • The awards are granted as restricted awards over ADS for US participants and as nil-cost options over Ordinary Shares for all other participants.
  • The price of Ordinary Shares was £14.35 on the transaction date.
  • The price of American Depositary Shares (ADS) was $36.17 on the transaction date.

⚠️ This is an experimental project and this report is for informational purposes only and should not be considered investment advice. Conduct your own thorough research and consult with a qualified financial advisor before making any investment decisions. ⚠️